6Karstaedt AS, Jones N, Khoosal M, et al. The bacteriology of pulmonary tuberculosis in a population with high human immunodeficency viurs seroprevalence[J] .Int J Tuberc Lung Dis, 1998,2:312 ～ 316.
8Malkin JE, Prazuk T, Simonnet F, et al. Tuberculosis and human immunodeficiency virus infection in West Burkina Faso: clinical presentation and clinical evolution[ J]. Int J Tuberc Lung Dis, 1997,1:68 ～ 74.
9Fishman AP. Fishman's pulmonary diseases and disorders[ M]. New York:McGraw - Hill Companies, 1998,2103 ～ 2120.
10Perenboom RM, Richter C, Swai ABM, et al. Clinical features of HIVserpositive and HIV seronegative patients with tuberculosis lymphadenitis in Dares Salaam[ J]. Tuberc Lung Dis, 1995,76:401 ～ 406.
3Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ,Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources[J]. Lancet Infect Dis, 2010, 10(7) :489-498.
5Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretrovirat therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil[J]. AIDS, 2007,21(11):1441-1448.
6Ferebee SH. Controlled chemoprophylaxis trials in TB.. A general review[J].Adv Tuberc Res, 1970,17:28-106.
7Shen Y, Shen L, Sehgal P, Huang D, Qiu L, Du G, Letvin NL, Chen ZW. Clinical latency and reactivation of AIDS-related mycobacterial infections[J].Journal of Virology, 2004, 78 (24): 14023-14032.
8Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations[J]. PNAS, 2006,2(103): 7042--7047.
9Richard S, Kornbluth. Skin Test Responses as Predictors of Tuberculous Infection and of Progression in HIV-infected Persons[J].Annals of Internal Medicine, 1993, 119 (3) : 241 -- 243.
